Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.

BioAge Labs, Inc. Common Stock

BioAge is a platform-driven, clinical-stage biotechnology company that is mapping human aging to develop a pipeline of therapies that treat disease and extend healthy lifespan. Our proprietary platform encompasses >65M molecular measurements spanning 45+ years of human aging and unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. Our growing clinical-stage portfolio includes BGE-105, a first-in-class apelin receptor agonist that prevented muscle atrophy in a Ph1b study of older volunteers at bedrest. We are developing BGE-105 in parallel for ICU-related atrophies and for muscle preservation during GLP-1 weight loss therapy. The portfolio also includes novel internally discovered NLRP3 inhibitors for neurodegenerative and ocular diseases driven by inflammation. Our mission is to develop therapies that change the nature of aging and provide patients with years more healthy time. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others.

BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development.

At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.


AME Cloud Ventures

Andreessen Horowitz

Felicis

Pear VC

Redpoint

Bossanova Investimentos

Caffeinated Capital

Kaiser Foundation Hospitals

Elad Gil

Ling Wong

BioAge Labs

BioAge is pleased to announce plans to initiate a Phase 2 trial of our apelin receptor agonist azelaprag co-administered with tirzepatide for treatment of obesity. Under the terms of an agreement signed yesterday, Eli Lilly and Company will provide tirzepatide for the study, and Lilly’s Chorus organization will advise and assist BioAge on trial design and execution. The trial, planned to start in mid-2024, is designed to assess whether this drug combination can achieve increased overall weight loss with improved body composition.

https://lnkd.in/gnpq_Juh

👇🏼 Keep reading for more background & why we’re excited for the trial:

• Azelaprag is an oral drug for the future of obesity therapy: Co-administration has the potential to achieve best-in-class weight loss with next-generation oral incretins currently in the pipeline, whose performance lags behind injectables. Our goal is 20–25% healthy weight loss with a completely oral drug combination.

• We are collaborating with a global leader in obesity: We are thrilled to work directly with the clinical development experts at Chorus and benefit from Lilly’s experience in obesity drug development. We are proud to collaborate with Lilly in one of their most important and competitive areas. 

• Our promising preclinical data points to greater — and healthier — weight loss: In diet-induced obese (DIO) mice, co-administration with azelaprag substantially increased weight loss achieved on tirzepatide alone. In addition, the combination normalized body composition to that of lean controls and decreased blood glucose levels

• Apelin signaling has been demonstrated to have multiple benefits for energy metabolism — and in our Phase 1b trial, azelaprag promoted muscle metabolism and protein synthesis while being well tolerated in healthy volunteers. 	

• The planned trial will advance BioAge’s mission of extending healthy lifespan in a new indication: Treating obesity has the potential to prevent or delay multiple diseases of aging for a large segment of the population.


Learn more about azelaprag, the apelin pathway, and obesity on our website:
https://lnkd.in/gSRkyM-t


BioAge is proud to sponsor Longevity Global’s 2024 SF kickoff event on Tuesday, Jan 30: afternoon co-working at the beautiful Savills space in downtown San Francisco, followed by lightning pitches and networking over drinks and food. Bring your laptop and co-work with friends (1–5 pm), and then pitch your longevity idea in the early evening (5–7:30).

See invite for details: https://lu.ma/f1mtzklu
Registration is free for first-time attendees of Longevity SF events.

See you there!

We got 2024 off to a great start with BioAge’s annual panel discussion & reception during JPM Healthcare Week. In a conversation moderated by BioAge CEO Kristen Fortney, panelists Tracey McLaughlin (Professor, Stanford University School of Medicine), Rob Myers, MD (CMO, OrsoBio), Michael Davidson (CEO, NewAmsterdam Pharma), and Axel Haupt (Senior Vice President, Diabetes Clinical Development, Eli Lilly and Company) shared their thoughts on our theme of “Extending human healthspan: Obesity, metabolism, and aging”.

Key takeaways from their conversation:

✅ Many pathways link obesity, metabolic disorders, and aging — and targeting these common pathways may have benefits for treating chronic disease.

✅ Emerging drug targets like apelin, FGF21, CETP inhibitors, and others have effects on aging pathways as well as specific diseases like obesity, diabetes, and CVD. Combination therapies may have synergistic benefits.

✅ Challenges in studying drugs for prevention include long trial durations, the need for large sample sizes, identification of appropriate biomarkers, and lack of reimbursement incentives. Regulators and stakeholders need to collaborate on solutions.

✅ Biomarkers are advancing: lipids and CRP have potential for tracking metabolic health; advanced imaging may eventually be accepted for showing benefits on atherosclerosis; and Alzheimer's disease trials are moving towards biomarker-based approvals.

✅ Key upcoming readouts will provide more evidence on whether incretins and new mechanisms can improve cardiovascular and kidney outcomes. Studies on preserving muscle mass with weight loss and combination approaches for obesity are important.

✅ Precision medicine approaches, targeting treatments based on disease subtypes and underlying physiology, will come to the fore as the cardiometabolic space attracts more attention and resources. 

Many thanks to our brilliant panelists — and to all who attended and created such an enjoyable evening!

📸 Action shot! At abcam's 2023 Innate Sensing & Signaling in Immunology meeting in Boston this week, BioAge scientists Kevin Wilhelmsen, Sarah Tronnes, and Aditi Deshpande presented a poster on our novel class of NLRP3 inflammasome inhibitors, which we are developing for inflammatory and age-related diseases. 

BioAge’s AI-driven discovery platform revealed that NLRP3 levels rise with age and are positively correlated with all-cause mortality. To identify novel NLRP3 inhibitors, we screened billions of molecules in a DNA-encoded library (DEL) for compounds that bind purified NLRP3 protein, yielding drug-like compounds that functionally inhibit the NLRP3 inflammasome in vitro with comparable or superior potency relative to publicly known inhibitors.

https://lnkd.in/gmUffkJD

	Dec '14	Dec '15	Dec '16	Dec '17	Dec '22	Dec '23
net income	-46.42M -	-37.23M 19.81%	-22.48M 39.62%	-98.15M 336.65%	-39.72M 59.53%	-63.85M 60.75%
depreciation and amortization	1.37M -	4.16M 204.39%	9.16M 120.21%	9.35M 2.01%	129K 98.62%	162K 25.58%
deferred income tax
stock based compensation	6.95M -	4.79M 31.06%	3.58M 25.28%	5.18M 44.67%	2.54M 50.95%	3.02M 18.74%
change in working capital	-42.96M -	-53.03M 23.45%	4.95M 109.34%	17.84M 260.00%	795K 95.54%	6.71M 744.03%
accounts receivables	278.14K -	-581.07K 308.92%	-5.03K 99.14%	-3.67M 73,011.70%
inventory	1.22M -	-8.05K 100.66%	-2.77M 34,278.42%	32.37K 101.17%
accounts payables	819.27K -	-983.47K 220.04%	-10.04M 920.92%	34.88K 100.35%	994K 2,749.61%	-393K 139.54%
other working capital	-45.28M -	-51.46M 13.65%	17.77M 134.53%	21.44M 20.68%		3.31M -
other non cash items	58.61M -	49.11M 16.22%	-32.83M 166.86%	36.00M 209.65%	100K 99.72%	6.51M 6,413%
net cash provided by operating activities	-22.45M -	-32.20M 43.41%	-37.62M 16.82%	-29.79M 20.81%	-36.18M 21.46%	-37.36M 3.26%
investments in property plant and equipment					-103K -	-166K 61.17%
acquisitions net
purchases of investments						-100K -
sales maturities of investments
other investing activites	-88.89M -	-66.76M 24.90%	-421.57K 99.37%	-587.20K 39.29%
net cash used for investing activites	-88.89M -	-66.76M 24.90%	-421.57K 99.37%	-587.20K 39.29%	-103K 82.46%	-266K 158.25%
debt repayment	-25M -	-16.06M 35.77%	-15.31M 4.65%	-19.05M 24.40%	-2.50M 86.88%	-35M 1,300%
common stock issued	36.25M -	33.28M 8.19%	18.48M 44.47%	37.98M 105.52%
common stock repurchased	-51.04M -	-6.97M 86.34%	-16.16M 131.73%	-4.63M 71.34%
dividends paid
other financing activites	118.45M -	44.64M 62.31%	60.22M 34.89%	4.55M 92.44%	-45K 100.99%	-63K 40%
net cash used provided by financing activities	78.65M -	54.89M 30.22%	47.22M 13.96%	18.85M 60.09%	2.50M 86.74%	34.94M 1,298.20%
effect of forex changes on cash	-3.87M -	-1.96M 49.46%	246.40K 112.60%	224.04K 9.08%	246K 9.80%
net change in cash	-32.69M -	-44.07M 34.83%	9.19M 120.85%	-11.53M 225.49%	-33.54M 190.93%	-2.69M 91.99%
cash at beginning of period	83.73M -	51.04M 39.04%	6.97M 86.34%	16.16M 131.73%	61.18M 278.61%	27.64M 54.82%
cash at end of period	51.04M -	6.97M 86.34%	16.16M 131.73%	4.63M 71.34%	27.64M 496.85%	24.96M 9.72%
operating cash flow	-22.45M -	-32.20M 43.41%	-37.62M 16.82%	-29.79M 20.81%	-36.18M 21.46%	-37.36M 3.26%
capital expenditure					-103K -	-166K 61.17%
free cash flow	-22.45M -	-32.20M 43.41%	-37.62M 16.82%	-29.79M 20.81%	-36.28M 21.80%	-37.53M 3.43%

BIOA

COM:BIOAGELABS

BioAge Labs

Last Close

19.14

22/11 21:00

Market Cap

183.19M

Beta: -

Volume Today

157.82K

Avg: -

Preview